- Home
- BL vs ACLX Comparison
BL vs ACLX Comparison
Compare BL & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BL
- ACLX
- Stock Information
- Founded
- BL 2001
- ACLX 2015
- Country
- BL United States
- ACLX United States
- Employees
- BL N/A
- ACLX N/A
- Industry
- BL Computer Software: Prepackaged Software
- ACLX Biotechnology: Pharmaceutical Preparations
- Sector
- BL Technology
- ACLX Health Care
- Exchange
- BL Nasdaq
- ACLX Nasdaq
- Market Cap
- BL 3.4B
- ACLX 3.3B
- IPO Year
- BL 2016
- ACLX 2022
- Fundamental
- Price
- BL $56.20
- ACLX $62.99
- Analyst Decision
- BL Buy
- ACLX Strong Buy
- Analyst Count
- BL 12
- ACLX 13
- Target Price
- BL $60.75
- ACLX $111.55
- AVG Volume (30 Days)
- BL 716.2K
- ACLX 1.1M
- Earning Date
- BL 05-06-2025
- ACLX 05-08-2025
- Dividend Yield
- BL N/A
- ACLX N/A
- EPS Growth
- BL 28.07
- ACLX N/A
- EPS
- BL 1.41
- ACLX N/A
- Revenue
- BL $662,806,000.00
- ACLX $76,809,000.00
- Revenue This Year
- BL $10.08
- ACLX N/A
- Revenue Next Year
- BL $8.70
- ACLX $119.90
- P/E Ratio
- BL $39.67
- ACLX N/A
- Revenue Growth
- BL 8.93
- ACLX N/A
- 52 Week Low
- BL $40.82
- ACLX $47.86
- 52 Week High
- BL $66.25
- ACLX $107.37
- Technical
- Relative Strength Index (RSI)
- BL 69.21
- ACLX 52.91
- Support Level
- BL $54.70
- ACLX $60.67
- Resistance Level
- BL $55.44
- ACLX $64.78
- Average True Range (ATR)
- BL 1.00
- ACLX 4.09
- MACD
- BL -0.01
- ACLX 0.42
- Stochastic Oscillator
- BL 90.54
- ACLX 59.15
About BL BlackLine Inc.
BlackLine Inc is engaged in providing financial accounting close solutions delivered as Software as a Service (SaaS). The Company's solutions enable its customers to address various aspects of their critical processes, including financial close & consolidation, intercompany accounting, and invoice-to-cash. The majority of the revenue of the company is earned in the United States.
About ACLX Arcellx Inc.
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.